Tirzepatide 'Plus' formulas: upgraded science or upgraded marketing?

What did @drkameshaglp1 actually say?

The creator, identifying KinMeds as her provider, told viewers that because the FDA removed tirzepatide from the drug shortage list, compounding pharmacies had to either drop the drug or change their formulation. KinMeds, she says, chose to change it, adding B vitamins to create what they're calling "tirzepatide plus." She frames this as an upgrade, claiming viewers get "the same clinical effects of tirzepatide plus the benefits of having B vitamins" for side effects like nausea and low energy, all at the same price. She closes with a referral code for $25 off. To her credit, she does acknowledge the FDA's enforcement action rather than pretending it doesn't exist. But the leap from "we added B vitamins" to "you're getting a better product" is where things get complicated, and the video doesn't slow down long enough to examine that claim seriously.

Does the science back this up?

The GLP-1 and GIP mechanism she describes is accurate. The B vitamin claims are where the evidence gets thin. There is a known, real concern that metformin, not tirzepatide, depletes B12 over time. GLP-1 receptor agonists do cause nausea in a significant share of users, but the clinical fix for that is dose titration and dietary adjustments, not B vitamin supplementation. A 2022 review by Nauck and D'Alessio in Nature Reviews Endocrinology covers the dual agonism of tirzepatide thoroughly, with no mention of B vitamin co-administration as a clinical strategy. B6 and B12 have been studied for nausea in pregnancy (notably, the Cochrane review by Matthews et al., 2015) but that evidence does not automatically transfer to GLP-1-induced nausea, which has a different mechanism involving delayed gastric emptying and central appetite signaling. No peer-reviewed trial has tested tirzepatide plus B vitamins as a combination formulation for efficacy or side effect reduction.

What did they get wrong (or right)?

She got the regulatory situation basically right. The FDA did remove tirzepatide from the shortage list in early 2025, and compounding pharmacies were given a wind-down period, though legal challenges from compounders complicated the timeline. That part of her explanation is fair and useful context for patients who are confused.

What she got wrong, or at least dramatically oversold, is the "better product" framing. Adding B vitamins to a compounded formulation is a regulatory strategy as much as a clinical one. Under 503A and 503B compounding rules, changing the formulation, such as adding a "plus" ingredient, can be used to argue the compound is meaningfully different from the FDA-approved drug. Calling this an upgrade for the patient conflates a legal workaround with a clinical improvement. There is no published evidence that this combination outperforms tirzepatide alone for weight loss, blood sugar control, or even nausea reduction.

It also bears saying: compounded tirzepatide is not the same as Zepbound or Mounjaro. Potency, sterility standards, and bioavailability can vary between compounders. She does not mention this at all.

What should you actually know?

If you were getting compounded tirzepatide and your pharmacy is now offering a "plus" version with added B vitamins, ask your prescriber two direct questions: what is the evidence that this combination reduces side effects, and is this change primarily clinical or regulatory in motivation? Those are not the same thing, and you deserve an honest answer to both.

B vitamins are generally safe at standard doses, so the addition is unlikely to harm you. But "unlikely to harm you" is not the same as "clinically superior." The SURMOUNT trials that established tirzepatide's weight loss profile (Jastreboff et al., 2022, New England Journal of Medicine) did not include B vitamin co-administration. Extrapolating benefit from those results to a modified compound is not scientifically sound.

If you are on GLP-1 therapy and experiencing nausea, the standard clinical approach is slower dose titration, eating smaller meals, and avoiding high-fat foods, strategies backed by the prescribing guidance for both Zepbound and Mounjaro. If nausea is severe or persistent, talk to your provider about adjusting your dose. No supplement replaces that conversation.